Vaccine for New Covid-19 Variants may Take 6 to 9 Months

During this week's preliminary trials, it was revealed that Oxford-AstraZeneca jab provided little protection against mild to moderate infection, but not against severe disease and death.

AstraZeneca, a pharmaceutical company said that it can take 6 to 9 months to produce Covid-19 vaccines that are effective and can fight against the new variants of the virus.

A six-month turnaround for an updated vaccine would represent a vast improvement over traditional vaccine development timelines, The Guardian reported on Thursday.

Sri Lanka Approved AstraZeneca's Vaccine for Emergency Use
Sri Lankan authorities on Friday granted approval for the emergency use of the Oxford-AstraZeneca COVID-19 vaccine, Minister for Pharmaceutical Production and Regulation Channa Jayasumana said.

‘During this week's preliminary trials, it was revealed that Oxford-AstraZeneca jab provided little protection against mild to moderate infection, but not against severe disease and death.’

"Work on the variants hasn't started today, it started weeks and months ago, as soon as those new variants were identified and... we are aiming to be in the clinic in the spring, with next generation vaccines for the new variants," said Sir Mene Pangalos, Executive Vice-President, BioPharmaceuticals R&D at AstraZeneca.

Pangalos added that the jabs could be available to the public by the autumn, assuming the regulatory bodies are satisfied with using studies into the body's immune response to the vaccine as the route to approval.

The company's vaccine, developed jointly with the University of Oxford, remains effective against the original virus and at least one variant, first discovered in Kent, England. But preliminary findings in a small-scale trial prompted South Africa to limit its use while it ascertains its efficacy against the variant that emerged there, the report said.

Drugmaker AstraZeneca is Facing Tough Questions From Experts
After disclosing promising results from its COVID-19 vaccine trial earlier this week, drugmaker AstraZeneca is now facing tough questions from experts, especially after the company.

A number of Covid vaccines have shown lower efficacy in trials where the South Africa variant predominates -- earlier this week preliminary trials revealed the Oxford-AstraZeneca jab provided little protection against mild to moderate infection, although it is still expected to protect against severe disease and death.

It has recently emerged that some cases of the Kent variant have a mutation also found in the South African variant, a development that scientists have cautioned needs to be taken seriously, not least since the mutation -- known as E484K -- has been linked to the ability for the South African variant to evade protection offered by some current Covid vaccines, the report said.

AstraZeneca May Up Vaccine Supply to European Union
European Commission President Ursula von der Leyen said that AstraZeneca, the Pharmaceutical company has promised to increase its vaccine supply to the European Union (EU).

Panaglos said tests need to be carried out on the Kent variant with the E484K mutation.

Oxford-AstraZeneca Vaccine Cleared by Expert Panel
India is just one step away from its first coronavirus vaccine. Soon, the approval will pave the way for the vaccine's rollout in India.

Source-IANS